Modulation of Ca2+ channel currents by a novel antidementia drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960) in rat hippocampal neurons.
The Journal of pharmacology and experimental therapeutics • Vol. 308, Issue 1 • 2004
The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease.
Expert opinion on investigational drugs • Vol. 13, Issue 1 • 2004
Effect of N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), an antidementia drug with a novel mechanism of action, on regional cerebral blood flow and glucose metabolism in aged rhesus macaques studied with positron emission tomography.
The Journal of pharmacology and experimental therapeutics • Vol. 306, Issue 1 • 2003
Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine • Vol. 44, Issue 1 • 2003
